Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LVNG RX vs TeleFirst Med

LVNG RX
Graded #272

Higher grade

vs+5.100000000000001
TeleFirst Med
Graded #400

Lower grade

The verdict

LVNG RX takes it — 62.5/100 to 57.4/100.

LVNG RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LVNG RX is a Delaware-registered telehealth platform (LVNG RX LLC) offering compounded semaglutide from $149/mo and tirzepatide from $249/mo, plus a lower-dose GLP-1 microdose program.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLVNG RX +19
64
45
Dose & formulationLVNG RX +11
64
53
Clinical oversightTeleFirst Med +26
56
82
Labs & monitoringLVNG RX +10
62
52
FulfillmentLVNG RX +11
69
58
Contract termsLVNG RX +6
61
55
LVNG RX · left barTeleFirst Med · right bar

The numbers

MetricLVNG RXTeleFirst Med
WeighScore62.5/10057.4/100
GradeCC
Scorecard rank#272#400
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (microdose tier, starting dose, compounded)Not disclosed
CoverageCoverage not published2 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
LVNG RX

Graded #272 · C

Strengths

  • One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
  • States you are charged nothing if a provider does not approve you for treatment
  • Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
  • Semaglutide from $149/mo is competitive against the wider compounded market
  • Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide

Where it loses points

  • Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
  • Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
  • Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
  • The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
  • No compounding pharmacy, medical group or individual clinician is named anywhere on the site
TeleFirst Med

Graded #400 · C

Strengths

  • Prescribes real brand-name GLP-1 (e.g. Ozempic/Wegovy), not compounded — appealing if you specifically want FDA-approved branded medication
  • Simple $120 telehealth evaluation with a licensed doctor; no insurance hassle and no prior authorization
  • You fill the prescription at your own regular pharmacy rather than waiting on a mail-order compounding pharmacy
  • Also a general telehealth clinic (urgent care, chronic-condition management) if you want broader care

Where it loses points

  • Only Texas and North Carolina are confirmed — not available nationwide
  • The $120 is an evaluation fee; the brand-name medication is billed separately at your pharmacy and can be expensive without insurance
  • Small practice (about 500 patients) with limited public detail on its clinicians and program
  • No compounded or lower-cost medication option, and no medication pricing is published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard